5.6. COVID-19 infection
Restrictions:
For treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test only if:
- they have 1 or more risk factors for progression to severe COVID-19 (as defined in section 5 of
NICE’s technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for
treating COVID-19) and - both nirmatrelvir plus ritonavir and sotrovimab are contraindicated or unsuitable.
For use in accordance with current NHSGGC prescribing guidance for COVID-19 (see here for a brief overview of the therapeutic management of each patient group).
Prescribing Notes:
Supply in primary care is via HSCP Pharmacists.
Restrictions:
Restricted to use in patients with increased risk for progression to severe COVID-19 in accordance with current NHSGGC prescribing guidance for COVID-19 (see here for a brief overview of the therapeutic management of each patient group).
Prescribing Notes:
Supply in primary care is via HSCP Pharmacists.

Restrictions:
For treatment of COVID-19 patients in hospital, only if they have a high risk of serious illness. For use in accordance with current NHSGGC prescribing guidance for COVID-19 (see here for a brief overview of the therapeutic management of each patient group).

Restrictions:
Restricted to use in accordance with current NHSGGC prescribing guidance for COVID-19 (see here for a brief overview of the therapeutic management of each patient group) for patients with increased risk of progression to severe COVID-19 where nirmatrelvir and ritonavir is contraindicated or unsuitable.

Restrictions:
Restricted to use in accordance with current NHSGGC prescribing guidance for COVID-19 (see here for a brief overview of the therapeutic management of each patient group).